Valuation: Allied Corp.

Market Cap 1.3M 1.16M 1.07M 975K 1.83M 123M 1.86M 12.93M 5.09M 64.7M 4.89M 4.79M 205M P/E 2023
-2.13x
P/E 2024 -2.52x
Enterprise Value 7.55M 6.74M 6.22M 5.65M 10.6M 715M 10.76M 74.91M 29.51M 375M 28.34M 27.74M 1.19B EV / Sales 2023
394,366,816x
EV / Sales 2024 171,944,593x
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
Current year 0
Extreme 1.0E-6
0.01
1 year 0
Extreme 1.0E-6
0.01
3 years 0
Extreme 1.0E-6
0.25
5 years 0
Extreme 1.0E-6
2.15
10 years 0
Extreme 1.0E-6
4.5
Manager TitleAgeSince
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer 71 -
Corporate Officer/Principal - 02/05/2020
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - 02/05/2020
Director/Board Member - 21/10/2024
Date Insider Type Main position Quantity % Market Cap. Importance
25/4/23 Buy

Director

80,000 0.0824%
22/9/20 Buy

Chief Executive Officer

10,000 0.0118%
22/9/20 Other

Chief Executive Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 117
+2.83%+4.40%+60.84%+123.50% 1,165B
+3.81%+5.66%+38.70%+74.91% 645B
+0.14%+0.63%+24.71%+95.03% 504B
-0.40%+3.06%+43.89%+64.51% 380B
-1.76%+1.41%+68.06%+43.41% 363B
-0.47%+2.95%+22.83%+51.93% 297B
-1.75%+2.64%+2.22%+26.48% 269B
+2.04%+3.05%+51.12%+60.42% 237B
+2.36%-0.11%+29.42%+102.04% 195B
Average -0.29%+2.29%+37.98%+71.36% 405.55B
Weighted average by Cap. -0.31%+3.17%+43.13%+83.13%

Financials

2023 2024
Net sales 0.07 0.06 0.06 0.05 0.1 6.83 0.1 0.72 0.28 3.58 0.27 0.26 11.33 0.1 0.09 0.08 0.07 0.13 9.11 0.14 0.95 0.38 4.77 0.36 0.35 15.12
Net income -10.68M -9.53M -8.79M -7.99M -14.98M -1.01B -15.21M -106M -41.72M -530M -40.07M -39.21M -1.68B -3.98M -3.55M -3.27M -2.97M -5.58M -377M -5.67M -39.44M -15.54M -197M -14.93M -14.61M -625M
Net Debt 5.65M 5.04M 4.65M 4.23M 7.93M 535M 8.05M 56.07M 22.09M 280M 21.21M 20.76M 889M 6.25M 5.58M 5.14M 4.67M 8.77M 592M 8.9M 61.98M 24.41M 310M 23.45M 22.95M 982M
Projected Income Statement - Annual - Allied Corp.
Logo Allied Corp.
Allied Corp. is an international medical cannabis production company. The Company is engaged in researching, creating, and producing targeted cannabinoid health solutions. It focuses on the development of Colombian produced medicinal cannabis for patients with conditions potentially suitable for treatment. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder (PTSD), Parkinson’s disease, Tourette’s syndrome, irritable bowel syndrome (IBS) and spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI). Its core hemp-derived cannabidiol (CBD) brands are Tactical Relief Brand, Equilibrium Bio and MaXXa. The Tactical Relief brand's flagship product is a hemp-derived CBD tincture for sale in the United States. The Equilibrium Bio brand is primarily focused on hydration and recovery areas. The MaXXa brand develops natural CBD-infused cosmetics and beauty products.
Employees
-
  1. Stock Market
  2. Stocks
  3. ALID Stock